NCT05308654: Phase 1: A Study to Assess activity & AEs in RRMM Receiving Oral ABBV-453 Tablets
NCT05227144: Phase 1: Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma
NCT05556616: Phase 1: A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma
NCT05338775: Phase 1: Talquetamab and Teclistamab Each with (PD-1) Inhibitor RRMM - (TRIMM-3)
NCT05431608: Phase 1: A Study of MCARH109 and MCARH125 in People With Multiple Myeloma
NCT05182073: Phase 1: FT576 in Subjects With Multiple Myeloma
NCT05219721: Phase 1: A Study of CAR-GPRC5D in Patients With RRMM Myeloma or Plasma Cell Leukemia
NCT05259839: Phase 1: IV Infused ABBV-383 With Anti-Cancer Regimens for Relapsed/Refractory Myeloma
NCT04398745: Phase 1: Belantamab Mafodotin With Normal and Varying Degree of Impaired Renal Function
NCT05016778: Phase 1: (OriCAR-017) - CAR-T Cells Targeting GPRC5D in the Treatment of RRMM - POLARIS
NCT05020444: Phase 1 - TriPRIL CAR T Cells in Multiple Myeloma
NCT05050097: Phase 1 - A Study of Talquetamab With Other Anticancer Therapies in Multiple Myeloma
NCT05024045: Phase 1 - Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
NCT04754100: Phase 1 - AGENT-797 in Participants With Relapsed/Refractory Multiple Myeloma
NCT05153330: Phase 1: Study of BMF-219, in Adult Patients With Multiple Myeloma, Lymphoma, Leukemia
NCT04772989: Phase 1: A Study to Evaluate AB308 in Combination With AB122 in Participants With MM
NCT04702425: phase 1: VOB560-MIK665 Combination First in Human Trial in Patients With Hem. Malig.
NCT05027594: Phase 1: Study of NMS-03597812 in Adult Pts With Relapsed or Refractory Myeloma
NCT05139225: Phase 1: A Study of TTI-621 and TTI-622 in Combination With Daratumumab RRMM